The Research Division of BioTelemetry

BioTelemetry Research, (Cardiocore & VirtualScopics) is an industry leader in clinical trials testing services, monitoring, data, and scientific consulting. Our comprehensive offerings provide global clients with world-leading technology, data management, and consulting services, streamlining the clinical trials process, and ensuring optimal research performance.

Every day, BioTelemetry Research’s global clinical trials services team meets the demands of Phase I–IV studies for the world’s largest pharmaceutical organizations, specialty pharmaceutical firms, emerging biotechnology companies, and medical device manufacturers. Providing a full range of centralized clinical trials testing modalities for both safety and endpoint evaluation, our core offerings include:

Comprehensive Testing Services for Clinical Trials

Today as BioTelemetry Research, we are a member of the world’s largest cardiac data network — processing over 2 billion heartbeats a day, while supporting more than 20,000 sites and 30,000 devices monthly, as well as monitoring over 500,000 patients a year. In addition to industry-leading global cardiovascular monitoring, we have now expanded our clinical trial services in two important areas: advanced imaging services for oncology, neurologic, cardiac, and musculoskeletal imaging, and a global alliance for respiratory testing and clinical trials expertise.


Dec 1, 2016

BioTelemetry, Inc. Announces Acquisition of Telcare’s Remote Diabetes Management Platform

BioTelemetry, Inc. (NASDAQ:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, is pleased to announce the acquisition of Telcare Medical Supply, Inc. and associated assets (“Telcare”), increasing the Company’s presence in the large and rapidly growing digital population health management […]

Read More More News


Oct 26, 2016

Non-invasive Quantification of Fatty Liver Disease

Jennifer Dolan Fox, Ph.D.; 1 Sep 2015

Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatisis (NASH) are emerging as the most prevalent causes of liver disease in Western countries. It is estimated that nearly 6 million Americans have NASH and nearly 600,000 have NASH-related cirrhosis. Download our whitepaper to learn more.

More Publications


Apr 13, 2017 | 11:00 AM

Assessing NASH: Discover the Non-invasive Techniques

Join BioTelemetry Research’s Jonathan Riek, PhD, Vice President, Musculoskeletal and Metabolic Imaging and Dr. Richard Ehman, MD from the Mayo Clinic as they discuss noninvasive ways to assess NASH using imaging, including proton density fat fraction (PDFF), T1 relaxometry, Magnetic resonance elastography (MRE) and the latest advances in MRE.

View Archive More Webinars


More Events